THPO

THPO (thrombopoietin/MGDF) is the lineage-specifying cytokine for megakaryopoiesis, acting as the ligand for the c-mpl receptor to drive megakaryocyte proliferation, maturation, and platelet production (PMID:7492757). In vivo, chronic THPO overexpression in mice produces lineage-restricted megakaryocyte expansion with 4–8-fold elevated platelets, myelofibrosis, and osteosclerosis without perturbing other hematopoietic lineages (PMID:7492757), and recombinant THPO selectively stimulates dose-dependent thrombopoiesis and megakaryocyte enlargement in primates (PMID:8948024). At the receptor level, THPO binding to c-mpl triggers tyrosine phosphorylation of JAK2 and the c-mpl receptor, the proximal signaling event underlying its effects on platelets and progenitors (PMID:11012184, PMID:8578535, PMID:9096694). Beyond mature megakaryocytes, THPO supports proliferation and survival of CD34+CD61+ megakaryocyte progenitors and broader progenitor populations including BFU-E and granulocyte-macrophage CFC, and can modulate erythroid gene expression in bipotent c-mpl-expressing progenitors (PMID:9007220, PMID:9332307). THPO expression is tightly controlled at both transcriptional and translational levels: transcription depends on ETS1 and STAT4 binding to the promoter, and its mRNA carries a suppressive out-of-frame upstream ORF7 in the 5'-UTR that normally restrains translation (PMID:36226497, PMID:38548144). This regulatory architecture is the basis of two opposing Mendelian disorders: a homozygous promoter mutation (c.-323C>T) that abolishes ETS1/STAT4 binding and impairs THPO expression causes congenital amegakaryocytic thrombocytopenia (PMID:36226497), while hereditary thrombocythemia mutations relieve ORF7-mediated translational suppression—either through exon 3 skipping that deletes ORF7 or a frameshift that brings ORF7 in-frame with the THPO start codon—yielding increased THPO protein (PMID:37962621, PMID:38548144).

1. 1995 Medium

   Establishing that THPO is the physiological c-mpl ligand and defining the lineage scope of its action answered whether a single cytokine specifies megakaryopoiesis in vivo.

   Evidence Retroviral overexpression of MGDF in mice with hematological and histological readout

   PMID:7492757

   Open questions at the time

   • Overexpression phenotype does not establish endogenous requirement
   • Myelofibrosis/osteosclerosis as secondary consequences not mechanistically dissected
2. 1995 High

   Genomic characterization defined the THPO locus architecture, mapping it to 3q26.3 and assigning the coding sequence to exons 3–7, providing the structural framework later needed to interpret regulatory and disease mutations.

   Evidence Genomic cloning, cDNA sequencing, and chromosomal mapping

   PMID:7822271

   Open questions at the time

   • Functional significance of the two fetal-liver splice variants not determined
   • 5'-UTR regulatory ORF not yet recognized at this stage
3. 1995 Medium

   Demonstrating that THPO sensitizes platelets to aggregating agents and induces platelet protein tyrosine phosphorylation extended its role from megakaryocyte production to direct modulation of mature platelet function.

   Evidence In vitro platelet aggregometry with soluble c-mpl blocking and phosphorylation Western blot

   PMID:8578535

   Open questions at the time

   • Identity of the ~85/130 kDa phosphoproteins not established
   • Physiological relevance of platelet sensitization unclear
4. 1996 Medium

   Primate dosing with native versus heat-inactivated recombinant THPO confirmed lineage-specific, structure-dependent thrombopoietic activity in a clinically relevant model.

   Evidence Subcutaneous recombinant MGDF administration in baboons with platelet counting and marrow biopsy

   PMID:8948024

   Open questions at the time

   • Receptor-level mechanism not addressed in this model
   • Long-term effects and marrow fibrosis not assessed
5. 1997 Medium

   Progenitor clonogenic assays revealed THPO supports survival and proliferation beyond the megakaryocyte lineage, including erythroid and granulocyte-macrophage progenitors and modulation of erythroid gene expression in bipotent progenitors.

   Evidence Single-cell clonogenic assays, c-mpl-expressing progenitor cell lines, and globin mRNA analysis

   PMID:9007220 PMID:9332307

   Open questions at the time

   • In vivo significance of broader progenitor survival not established
   • Mechanism of erythroid gene modulation not defined
6. 1997 Medium

   Correlating THPO responsiveness with c-mpl-dependent tyrosine phosphorylation in primary AML blasts tied functional output to receptor signaling competence.

   Evidence Proliferation and clonogenic assays with phosphorylation Western blot on primary AML cells

   PMID:9096694

   Open questions at the time

   • Identity of the ~90 kDa phosphoprotein not determined
   • Relevance to leukemogenesis not addressed
7. 1998 Medium

   Identifying JAK2 and c-mpl tyrosine phosphorylation as the proximal signal clarified the kinase axis transducing THPO action, while the absence of enhanced arterial thrombosis bounded its in vivo prothrombotic effect.

   Evidence In vitro/ex vivo platelet phosphorylation assays plus a rabbit carotid artery thrombosis model

   PMID:11012184

   Open questions at the time

   • Downstream effectors of JAK2 in platelets not mapped
   • Discrepancy between platelet sensitization and lack of thrombosis unexplained
8. 2023 Medium

   Linking a THPO promoter mutation to loss of ETS1/STAT4 binding established the transcriptional control of THPO and its loss-of-function disease mechanism, validated by therapeutic rescue.

   Evidence Promoter bioinformatics, in vitro transcription factor binding assays, serum THPO measurement, and eltrombopag clinical response in CAMT

   PMID:36226497

   Open questions at the time

   • Single case/family limits generality
   • Direct in vivo confirmation of ETS1/STAT4 occupancy at the endogenous locus not shown
9. 2023 Medium

   Defining a splice-donor mutation that triggers exon 3 skipping and removes a suppressive 5'-UTR upstream ORF revealed translational repression as the normal restraint on THPO, whose relief causes hereditary thrombocythemia.

   Evidence Mutant versus wild-type expression vectors with RT-PCR and protein quantification

   PMID:37962621

   Open questions at the time

   • Endogenous translational regulation in megakaryocytes not directly measured
   • Single-mutation analysis
10. 2024 High

    Systematic analysis of all six known hereditary thrombocythemia mutations consolidated two convergent mechanisms—ORF7 deletion via exon 3 skipping or ORF7 frameshift—both relieving translational suppression of THPO, unifying the gain-of-function disease class.

    Evidence Cloning of six mutant expression vectors with transcript and protein expression quantification

    PMID:38548144

    Open questions at the time

    • Quantitative contribution of ORF7 derepression to clinical platelet levels not modeled
    • Mechanism of ORF7-mediated suppression on ribosome scanning not detailed

• How THPO transcriptional control, ORF7-mediated translational repression, and c-mpl/JAK2 signaling are integrated to set physiological platelet set-point remains incompletely defined.
• No structural model of THPO–c-mpl engagement in the timeline
• Downstream JAK2 effectors and transcriptional outputs in megakaryocytes not mapped
• Identity of THPO-induced platelet phosphoproteins unresolved